Equities
Health CareMedical Equipment and Services
  • Price (USD)101.92
  • Today's Change-0.68 / -0.66%
  • Shares traded288.67k
  • 1 Year change-20.83%
  • Beta1.0745
Data delayed at least 15 minutes, as of May 02 2024 20:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Revvity, Inc. is a provider of health science solutions, technologies, and services, which delivers workflows from discovery to development, and diagnosis to cure. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The Life Sciences Segment applications include MicroBeta, The MuviCyte live-cell imaging system, The Signals Image Artist, The VICTOR Nivo multimode plate reader benchtop system, The EnSight multimode plate reader benchtop system, BioLegend LEGENDplex bead-based reagents, and The Quantum GX2 system. Its Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. It offers instruments, reagents, assay platforms and software to hospitals, and medical labs. It is focused on reproductive health, immunodiagnostics, and emerging market diagnostics.

  • Revenue in USD (TTM)2.73bn
  • Net income in USD183.35m
  • Incorporated1947
  • Employees11.50k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Olink Holding AB (publ) - ADR169.60m-31.60m2.82bn707.00------16.63-0.2547-0.25471.36--0.31450.99632.94239,882.60-5.86---6.40--67.49---18.63--3.55--0.0506--21.27---145.90------
Badger Meter Inc740.77m102.31m5.36bn2.14k52.5810.0240.807.243.473.4725.1318.221.083.078.39346,154.7014.8612.2618.1714.6039.2639.3813.8112.062.30--0.0036.3624.4010.1639.2527.226.7912.07
Vontier Corp3.10bn376.90m6.28bn8.00k16.817.0412.522.032.422.4219.845.770.71675.186.12386,900.008.7310.8011.1814.0446.2444.6212.1813.361.085.800.71942.24-2.803.03-6.08-0.50187.23--
Cognex Corp837.55m113.23m7.03bn2.99k62.744.6752.068.400.65250.65254.838.770.42131.666.67279,928.805.7010.636.2311.5671.7972.9713.5222.383.40--0.0057.03-16.750.7624-47.46-13.24-9.069.03
MKS Instruments Inc3.62bn-1.84bn7.72bn10.00k--3.12--2.13-27.56-27.5654.1736.950.35132.015.19362,100.00-17.86-1.60-19.57-1.7545.3544.95-50.84-3.252.011.160.6596--2.1111.78-652.85--6.692.44
Bio Rad Laboratories Inc2.67bn-637.32m9.24bn8.03k--0.8941--3.46-21.49-21.4991.24306.510.20711.655.43332,660.30-4.949.08-5.169.6053.5655.55-23.8641.974.340.30950.12070.00-4.673.1382.43--3.83--
Bruker Corp2.96bn427.20m11.49bn9.71k27.188.3321.223.872.912.9120.149.490.75421.646.15305,398.2010.858.3814.9911.4051.1749.8514.3911.390.994829.030.47569.8117.149.3644.0318.9116.794.56
Revvity Inc2.73bn183.35m12.67bn11.50k69.481.6220.644.651.481.2121.9663.520.19422.874.64237,011.001.314.761.465.3955.5257.196.7315.341.926.380.33076.52-16.95-0.1982-64.99-5.28-2.690.00
Avantor Inc6.87bn260.00m16.59bn14.50k63.833.1125.102.420.38260.382610.127.860.5255.325.71473,565.501.992.972.263.3533.6333.443.795.061.053.030.49940.00-7.263.51-51.52--31.17--
Waters Corp2.96bn642.23m18.74bn7.90k29.1316.2523.176.3410.8410.8449.9219.440.74772.464.15374,229.9016.2419.7720.2825.2959.5758.4521.7223.381.579.940.67190.00-0.52294.09-9.261.534.72--
Illumina Inc4.50bn-1.16bn19.86bn10.59k--3.45--4.41-7.34-7.3428.5136.130.40283.056.26425,306.90-10.37-6.20-12.87-7.2860.9566.39-25.75-15.481.29--0.2058---1.756.2173.64---7.91--
Veralto Corp5.04bn798.00m23.30bn16.00k29.2015.7226.354.623.233.2320.426.000.95566.406.17315,125.0015.12--19.09--58.31--15.83--1.5619.980.6376--3.10---0.7101------
Keysight Technologies Inc5.34bn969.00m25.30bn15.50k26.705.2621.164.745.435.4329.9727.540.61021.956.18358,523.5011.0711.6913.9214.2164.8162.0918.1417.751.44--0.27390.000.81187.10-5.9644.988.23--
Data as of May 02 2024. Currency figures normalised to Revvity Inc's reporting currency: US Dollar USD

Institutional shareholders

57.75%Per cent of shares held by top holders
HolderShares% Held
T. Rowe Price Investment Management, Inc.as of 31 Dec 202315.64m12.66%
The Vanguard Group, Inc.as of 31 Dec 202313.66m11.06%
Select Equity Group LPas of 31 Dec 202311.27m9.13%
Capital Research & Management Co. (Global Investors)as of 31 Dec 20237.67m6.21%
BlackRock Fund Advisorsas of 31 Dec 20236.07m4.91%
Janus Henderson Investors US LLCas of 31 Dec 20235.43m4.40%
SSgA Funds Management, Inc.as of 31 Dec 20235.18m4.20%
Geode Capital Management LLCas of 31 Dec 20232.70m2.19%
Independent Franchise Partners LLPas of 31 Dec 20231.93m1.56%
Mitsubishi UFJ Asset Management Co., Ltd.as of 31 Dec 20231.79m1.45%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.